Peng Lu Sells 300 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Peng Lu sold 300 shares of Pharvaris stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $34.00, for a total transaction of $10,200.00. Following the completion of the transaction, the insider directly owned 65,631 shares in the company, valued at $2,231,454. The trade was a 0.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Peng Lu also recently made the following trade(s):

• On Wednesday, April 29th, Peng Lu sold 3,733 shares of Pharvaris stock. The stock was sold at an average price of $30.06, for a total transaction of $112,213.98.
• On Thursday, April 30th, Peng Lu sold 15,000 shares of Pharvaris stock. The stock was sold at an average price of $30.24, for a total transaction of $453,600.00.
• On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.
• On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total transaction of $210,380.05.

Pharvaris Stock Performance

NASDAQ PHVS opened at $33.29 on Thursday. The firm’s fifty day moving average is $30.37 and its two-hundred day moving average is $27.88. Pharvaris N.V. has a one year low of $16.72 and a one year high of $34.41. The firm has a market cap of $2.18 billion, a PE ratio of -10.47 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.12. Research analysts predict that Pharvaris N.V. will post -3.22 earnings per share for the current year.

Analyst Ratings Changes

PHVS has been the topic of several analyst reports. Royal Bank Of Canada lowered their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Wolfe Research started coverage on Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price target for the company. Wall Street Zen raised Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Finally, Wedbush boosted their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $49.18.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently added to or reduced their stakes in PHVS. Tudor Investment Corp ET AL acquired a new stake in shares of Pharvaris in the 3rd quarter valued at approximately $1,943,000. Patient Square Capital LP boosted its stake in shares of Pharvaris by 41.4% in the third quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock valued at $8,617,000 after buying an additional 101,098 shares in the last quarter. Integral Health Asset Management LLC acquired a new position in Pharvaris during the third quarter worth $4,990,000. JPMorgan Chase & Co. grew its holdings in Pharvaris by 710.4% during the third quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock worth $676,000 after acquiring an additional 23,743 shares during the period. Finally, PSP Research LLC purchased a new position in Pharvaris in the fourth quarter worth $569,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.